secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276906
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports Phase 1b KOMET-001 data for ziftomenib in R/R AML; 600 mg shows 25% CR/CRh
--------------------------------------------------------------------------------

- Phase 1b at 600 mg (N=12): 25% CR/CRh rate, 33% composite CR (75% MRD-), 42% ORR.
- Phase 1a (N=30): 2 DLTs (pneumonitis at 400 mg, differentiation syndrome at 1000 mg); manageable safety.
- Differentiation syndrome occurred in 7 Phase 1b patients; severity declined after DS Guidance implementation.
- Oral presentation at ASH on Dec 10, 2022, will include preliminary data from 18 additional Phase 1b extension patients.
- Ziftomenib is an oral menin-KMT2A inhibitor targeting NPM1m and KMT2Ar relapsed/refractory AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312522276906/0001193125-22-276906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312522276906/d366823d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer